Cassava Sciences reported a cash balance of approximately $128.6 million as of December 31, 2024, and announced a 33% workforce reduction, affecting 10 employees, due to the discontinuation of its Phase 3 studies for simufilam in Alzheimer's disease, incurring an estimated $0.4 million in one-time costs.